Please login to the form below

Not currently logged in

FDA rejects Adventrx’s lung cancer drug Exelbine

Adventrx receives rejection from the FDA for its new non-small cell lung cancer drug, Exelbine, over authenticity issues

The US Food and Drug Administration (FDA) has rejected Adventrx Pharmaceuticals' New Drug Application (NDA) for Exelbine, a drug for the treatment of non-small cell lung cancer. Exelbine is a reformulated version of Pierre Fabre Pharmaceuticals' Navelbine.

This rejection from the FDA has caused shares in Adventrx Pharmaceuticals to plunge as much as 61 per cent.

In the complete response letter that Adventrx received, the FDA decided that it could not approve the Exelbine NDA in its present form as the “authenticity of the drug products used in the pivotal bioequivalence trial could not be verified, which placed the results of the trial into question”. It stated that this trial would have to be repeated in order to address the problem.

Adventrx is planning to request a meeting with the FDA to discuss the FDA's response to the application which contradicts the views of Adventrx, which believes that the authenticity of the drug products are verifiable.

11th August 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....